Coronavirus in Spain live: confinement, restrictions and curfew | Oxford vaccine


The second phasee of clinical trials of the vaccine against covid-19 developed by the English University of Oxford shows that is safe in healthy older people and elicits an immune response, reports this Thursday the medical journal “The Lancet”.

In collaboration with the pharmaceutical company AstraZeneca and other organizations, the researchers tested the preparation, called ChAdOx1 nCoV-19, in an experiment with 560 healthy adults, including 240 over 70 years, with the aim of observing its impact on the immune system and possible side effects.

The “promising preliminary results” indicate that this vaccine against the SARS-CoV-2 virus offers “similar safety and immunogenicity results in healthy older adults than in those between 18 and 55 years old.”

According to “The Lancet”, Phase 2 allows to conclude that the antidote causes “few side effects” and “induces an immune response in both parts of the immune system in all age groups with both a low and standard dose.”

According to the study, British vaccine elicits a T-cell response (able to find and attack virus-infected cells) fourteen days after the first dose, and an antibody response 28 days after the booster dose (which would attack the virus when circulating through the blood or lymphatic system).

The authors point out that Phase 3 of the clinical trials, which is underway, should confirm these results and determine “to what extent the vaccine is effective to protect against SARS-CoV-2 infection “in a broader and more heterogeneous group of people, including elderly people with previous pathologies.